We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Immupharma Plc | LSE:IMM | London | Ordinary Share | GB0033711010 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.14 | -6.86% | 1.90 | 1.84 | 1.96 | 2.01 | 2.00 | 2.00 | 1,925,128 | 16:35:20 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Finance Services | 0 | -3.81M | -0.0114 | -1.76 | 6.7M |
Date | Subject | Author | Discuss |
---|---|---|---|
30/3/2020 07:18 | So many questions come out of the RNS. Remember I am currently a shareholder so I want it to go up. Clearly more dilution is not good although the discount is marginal. The meeting with the FDA hasn't happened and I think the lack of experience of Avion is beginning to show. Why has it taken this long to get an advisory board together as that should be the first thing you do. As for the new indication for Lupuzor we need to know what dose the pre clinical studies were done at. If it was the same as before, in other words at doses much higher than in humans then they are meaningless. On the face of it the new projects are good news although it is impossible to assess the quality of those projects from the information given. So a bit of a curate's egg of an RNS. I have always wondered where that saying comes from so I am going to have to look it up! | nobbygnome | |
30/3/2020 07:15 | Financed for the future then,Company safe. | amaretto1 | |
30/3/2020 07:12 | Immupharma PLC GBP1.5m Subscription to fund R&D pipeline expansion | onehanson | |
27/3/2020 17:34 | There is going to be very significant disruption to clinical trials while Covid-19 remains with us. We are seeing significant numbers of clinicians mobilised to the front line and many other hospital activities, including ongoing clinical studies are being de-prioritised. Clinical research organisations that support clinical trials are not viewed as key workers so cannot be expected to have access to patients to collect data etc. Hospitals are certainly not going to be considering approving new trials until we are way beyond this crisis. We are also seeing organisations that review and assess medicines suspend their normal activities in order to help support the fight against Covid. Given all that is happening right now, I cannot see the planned study starting this year. FDA study approval is also far from guaranteed this year. EDIT: just seen this in the news | njb67 | |
27/3/2020 16:58 | Was a really good day..... monday might be even better | halfbutt | |
27/3/2020 10:00 | Could go above 10p on expectation and speculation... | halfbutt | |
27/3/2020 08:48 | Monday or Tuesday by the looks of it | tarny | |
27/3/2020 08:36 | When is good news coming ? | onehanson | |
26/3/2020 11:46 | Some good buying today, order books looks strong and news before Tuesday :) | tarny | |
25/3/2020 06:21 | Nobby, I believe meeting has already happened earlier this year. I’ve now send email to them to confirm. I doubt they will reply but will keep on pushing. | marie1980_m | |
24/3/2020 21:30 | >> Marie Because of the crisis the FDA may not be following the scheduled timetable so it will be no surprise if the meeting hasn't happened yet. Nothing to worry about... | nobbygnome | |
24/3/2020 20:39 | Strongly believe RNS tomorrow or lately by Friday. But instinct says tomorrow.. Looking at Tim’s track record, he must be waiting for right time to jump. Let’s see - if no RNS by Friday then I need to spend more time in learning/understandi Don’t think he will delay about FDA announcement because of Virus | marie1980_m | |
24/3/2020 16:24 | Can’t buy anything now.. My £13000 still waiting for 9p | marie1980_m | |
24/3/2020 15:29 | Nobby, Ifn-a is what we associate with Lupus sufferers , agreed Astra/ Neovacs are working on that ... The polyclonal avantage to Neovacs during this covid-19 outbreak imv | harleydocman | |
24/3/2020 14:10 | Buy is exact 9p but maximum £500 Crazy They are accepting sell upto £15000 at one to buy no buy more than £1K Insane | marie1980_m | |
24/3/2020 13:54 | Wow now they even wouldn’t let me buy even for £1000 Strange! | marie1980_m | |
24/3/2020 13:52 | Total £8k 24/03/2020 26/03/2020 B592262432 Immupharma Plc Ordinary 10p 46918 @ 8.5 8.5 46,918 -3,999.98 24/03/2020 26/03/2020 B592233992 Immupharma Plc Ordinary 10p 46627 @ 8.553 8.553 46,627 -3,999.96 | marie1980_m | |
24/3/2020 13:43 | Topped up £4K Immupharma Plc (IMM) Ordinary 10p 46627 shares bought at 8.553p Value: (Excl. stamp duty, commission and PTM levy) £3,988.01 PTM levy: £0.00 Commission: £11.95 Stamp duty: £0.00 Settlement date: 26/03/2020 Total value of trade: £3,999.96 | marie1980_m | |
24/3/2020 08:10 | My second tranche coming guys.. Booked profit from SNG | marie1980_m | |
24/3/2020 07:53 | The important inflammatory cytokine in lupus is interferon alpha not beta. | nobbygnome | |
24/3/2020 07:47 | A quick one | harleydocman | |
23/3/2020 16:11 | Nobby, We can agree on that .. but what seems to be happening is that some people are in an overdose of ifn to try and fight the virus ... Waiting on confirmation | harleydocman | |
23/3/2020 15:36 | Soto be clear you need beta interferon to fight the virus. | nobbygnome | |
23/3/2020 15:35 | Not interferon but maybe other cytokines such as TNF. Corona viruses have evolved to reduce the beta interferon production to evade the immune system. There is no doubt beta interferon is important for anti viral responses. | nobbygnome | |
23/3/2020 14:56 | Nobby, From what îam hearing ... It's complications on the overdrive of the immune system which is killing people ..autoimmune problems Over production of interferon might be the cause but waiting for more information What are your thoughts ? | harleydocman |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions